/ /

CLINICAL

How sleep affects the ocular surfaceAt every age we need adequate, uninterrupted sleep for optimal, wakeful functioning. Insufficient sleep is associated with a number of chronic diseases and conditions such as diabetes, cardiovascular disease, obesity, and depression.
Intense pulsed light bridges eye care and aestheticsWhat is this age-defying modern technology that a young, nonmedical professional is applying to her face? It is a YAG laser combined with an intense pulse light (IPL).
Trials making strides in identifying ROP risk factors, predictive modelsKey components in retinopathy of prematurity trials include risk factors, predictive models, telemedicine and tele-education trends, and treatment.
Limiting inflammation may decrease nerve damage, preserve cell functionEvidence supports the involvement of an important pathway in retinal ganglion cell dysfunction and death in traumatic optic neuropathy.
Novel glaucoma treatments factor in scleral behaviorInnovations in sustained-drug delivery and neuroprotection are bringing glaucoma specialists one step closer to additional therapeutic options.
DARPin molecule prolongs anti-VEGF activity in nAMDA phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.
No one imaging tool fits all in identifying AMD lesionsMultimodal imaging, including traditional and newer techniques, is necessary for identifying the spectrum of retinal lesions associated with age-related macular degeneration (AMD), said David Sarraf, MD.
Retina surgeon’s AMD regimen at center of Medicare fraud case
Retina surgeon’s AMD regimen at center of Medicare fraud caseEarlier this month, a jury convicted West Palm Beach retina surgeon Solomon Melgen, MD, on 67 counts of Medicare fraud. This high-profile case hit very close to home, as myself and another retina specialist from my own community were on opposing sides of the case.
Treating ROP: Laser associated with high success rate for retinopathy of prematurityLaser photocoagulation is a time-tested, well-defined, and effective treatment for retinopathy of prematurity (ROP) with requirements for follow-up that are much more manageable compared with anti-vascular endothelial growth factor (anti-VEGF) therapy, argued David K. Wallace, MD, MPH.
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I disease
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I diseaseAnti-VEGF therapy for Zone I retinopathy of prematurity (ROP) is associated with better structural and functional outcomes than laser therapy, but also a longer recurrence risk period, said Helen A. Mintz-Hittner, MD.